Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 299-307

  Andrews, Stephanie ^a   Holden, Rita ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b St Luke's Hospital   (United States)

Author keywords

Case studies; Immunotherapy; Ipilimumab; Melanoma

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; INFLIXIMAB; INTERLEUKIN 2; IPILIMUMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; VEMURAFENIB; VINBLASTINE;

ABDOMINAL PAIN; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EPISCLERITIS; ERYTHRODERMA; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; ILEUS; IMMUNOPATHOLOGY; INCONTINENCE; INTESTINE PERFORATION; IRITIS; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MOTOR NEUROPATHY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NAUSEA; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SENSORY NEUROPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VOMITING;

EID: 84866669341     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S31873     Document Type: Review

References (23)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
3. Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2008/. Accessed September 20, 2011.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27: 6199-6206.
5. National Comprehensive Cancer Network. Melanoma. 2012. Available from: http://www.nccn.org/index.asp. Accessed October 28, 2011.
6. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521melanoma patients with distant metastases. J Am Coll Surg. 1995;181: 193-201.
7. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipili-mumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5:557-561.
8. Margolin KA, Di Giacomo AM, Maio M. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin Oncol. 2010;37: 468-472.
9. Radbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer. 2004;101:825-833.
10. Staudt M, Lasithiotakis K, Leiter U, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;10:1213-1218.
11. Dummer R, Maio M, Hamid O, et al. Abstract P-0004 presented at the Perspectives in Melanoma XIV meeting, Amsterdam, The Netherlands; September 17-18, 2010.
12. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25: 5426-5434.
13. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9:587-595.
14. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
15. Zelboraf® (vemurafenib) package insert. South San Francisco, CA: Genentech USA Inc,; 2011.
16. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-723.
17. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37(5):533-546.
18. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517-2526.
19. Yervoy™ (ipilimumab) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
20. Ibrahim R, Berman D, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol. 2011;29 Suppl:Abstract 8583.
21. Bristol-Myers Squibb. Ipilimumab US prescribing information: risk evaluation and mitigation strategy (REMS). Available from: http://www.yervoy.com/hcp/rems.aspx. Accessed September 12, 2011.
22. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
23. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388-1397.